| Autor: |
Newton GK; Department of Medicinal Chemistry, Domainex Ltd. , 162 Cambridge Science Park, Cambridge CB4 0GH, United Kingdom., Perrior TR, Jenkins K, Major MR, Key RE, Stewart MR, Firth-Clark S, Lloyd SM, Zhang J, Francis-Newton NJ, Richardson JP, Chen J, Lai P, Garrod DR, Robinson C |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of medicinal chemistry [J Med Chem] 2014 Nov 26; Vol. 57 (22), pp. 9447-62. Date of Electronic Publication: 2014 Nov 17. |
| DOI: |
10.1021/jm501102h |
| Abstrakt: |
Blocking the bioactivity of allergens is conceptually attractive as a small-molecule therapy for allergic diseases but has not been attempted previously. Group 1 allergens of house dust mites (HDM) are meaningful targets in this quest because they are globally prevalent and clinically important triggers of allergic asthma. Group 1 HDM allergens are cysteine peptidases whose proteolytic activity triggers essential steps in the allergy cascade. Using the HDM allergen Der p 1 as an archetype for structure-based drug discovery, we have identified a series of novel, reversible inhibitors. Potency and selectivity were manipulated by optimizing drug interactions with enzyme binding pockets, while variation of terminal groups conferred the physicochemical and pharmacokinetic attributes required for inhaled delivery. Studies in animals challenged with the gamut of HDM allergens showed an attenuation of allergic responses by targeting just a single component, namely, Der p 1. Our findings suggest that these inhibitors may be used as novel therapies for allergic asthma. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
